Evidence map›Paper›PMID 41441494›Full record

ArticleNanomaterials (Basel, Switzerland)2025

Copper-Modified Mesoporous Silica Nanoparticles for Antimicrobial Applications.

Amaia M Goitandia, Maialen Argaiz, Miren Blanco, Giorgia Grilli, Elisa Recchia, Alessandra Amoroso, Nathalie Totaro, Andrea Ciammaruconi, Riccardo De Santis, Leire Ruiz Rubio and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amaia M GoitandiaUnidad de Química de Superficies y Nanotecnología, Fundación Tekniker, Iñaki Goenaga 5, 20600 Eibar, Spain.ORCID 0000-0003-2188-2850
Maialen ArgaizUnidad de Química de Superficies y Nanotecnología, Fundación Tekniker, Iñaki Goenaga 5, 20600 Eibar, Spain.
Miren BlancoUnidad de Química de Superficies y Nanotecnología, Fundación Tekniker, Iñaki Goenaga 5, 20600 Eibar, Spain.ORCID 0000-0003-0031-0394
Giorgia GrilliDefence Institute for Biomedical Sciences, 00184 Rome, Italy.ORCID 0009-0009-4993-6823
Elisa RecchiaDefence Institute for Biomedical Sciences, 00184 Rome, Italy.
Alessandra AmorosoDefence Institute for Biomedical Sciences, 00184 Rome, Italy.ORCID 0009-0009-1399-2794
Nathalie TotaroDefence Institute for Biomedical Sciences, 00184 Rome, Italy.
Andrea CiammaruconiDefence Institute for Biomedical Sciences, 00184 Rome, Italy.ORCID 0000-0002-5985-3767
Riccardo De SantisDefence Institute for Biomedical Sciences, 00184 Rome, Italy.
Leire Ruiz RubioMacromolecular Chemistry Group (LQM), Physical Chemistry Department, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.ORCID 0000-0002-2045-008X
Fabiana ArduiniDepartment of Chemical Science and Technologies, University of Rome "Tor Vergata", Via Della Ricerca Scientifica 1, 00133 Rome, Italy.
Florigio ListaDefence Institute for Biomedical Sciences, 00184 Rome, Italy.

Funding

European Union 101058570
6 · The paper itself

Abstract

The escalating global crisis of antimicrobial-resistant (AMR) bacterial infections, along with the continuous threat of viral outbreaks, poses a serious risk to public health worldwide and underscores the urgent need for innovative therapeutic strategies. In this study, mesoporous silica nanoparticles (MSNs) were successfully synthesized and subsequently functionalized with copper to impart broad-spectrum antimicrobial activity. The oxidation state of copper on the MSN surface was modulated through thermal treatments, allowing the evaluation of its influence on antimicrobial efficacy. The modified MSNs were tested against key bacterial pathogens, including

Indexed as

antibacterial propertiesE. coliinfluenza Amesoporous silica nanoparticles (MSNs)SARS-CoV-2S. aureusvirucidal propertiesvirus inactivation

Identifiers

PMID41441494
PMCPMC12736321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.